FRANKLIN, Mass., March 10, 2011 /PRNewswire/ — Echo
Therapeutics, Inc. (OTC Bulletin Board:
ECTE), a company developing its needle-free Symphony™
tCGM System as a non-invasive, wireless, transdermal continuous
glucose monitoring system and its Prelude™ SkinPrep System
for transdermal drug delivery, today announced that Patrick T.
Mooney, M.D., CEO, President and Chairman of the Board of Echo
Therapeutics will present at the ROTH 23rd Annual Growth
Dr. Mooney will make a corporate presentation to prospective
corporate partners and investors on Tuesday, March 15th at 3:30PM
PST. The Company’s presentation will be delivered at the Ritz
Carlton Laguna Niguel in Dana Point, California.
About Echo TherapeuticsEcho is developing the Symphony tCGM
System as a non-invasive, wireless, transdermal continuous glucose
monitoring system for patients with diabetes and for use in
hospital critical care units. Echo is also developing its
needle-free Prelude SkinPrep System as a platform technology for
enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:Patrick T. Mooney, M.D.
Media: Richard SternChairman and Chief Executive
Stern & Co.(508)530-0329